SYGNIS AG, today announced its subsidiaries Innova Biosciences, Expedeon Holdings, and C.B.S. Scientific have united as Expedeon, effective 1 March 2018.
The corporate rebranding follows the latest acquisition of Innova Biosciences by SYGNIS AG in June 2017. SYGNIS AG will continue to serve as the parent company and legal entity.
The corporate integration under the Expedeon brand name enables all organisations to take advantage of broad international sales and distribution networks, as well as in-house expertise and e-commerce channels. Customers will benefit from a larger sales footprint, service and support personnel in North America, Europe and Asia. Expedeon serves the genomic, proteomic and immunology research markets, which represent an opportunity approaching $ 100 billion worldwide. The SYGNIS Group has laboratory facilities and commercial sites in the UK, USA, Singapore, Germany and Spain, and a highly skilled workforce of over 100 employees worldwide.
Dr. Heikki Lanckriet, CEO and CSO of SYGNIS, said: “The successful execution of our ‘Grow, Buy and Build strategy’ has significantly enhanced our existing product portfolio, as well as our sales and marketing capacities. With the corporate rebranding, we bring together the Group of companies as Expedeon, in line with our vision to establish our position as a global brand for innovative reagents and services in the life sciences and diagnostics industries. The full integration of the Group supports this vision, and we are excited to continue moving the Company forward.”
The combined Expedeon product portfolio now comprises a wide range of complementary products and services to support the genomic, proteomic and immunology markets. As a fully integrated Company, Expedeon will continue to work toward increasing its market share with a growing range of cutting-edge tools and services to further benefit the research community worldwide. The combined product offering is accessible via the newly launched website www.expedeon.com.